NEURONTIN
Pronunciation: gab-a-PEN-tin (nyoo-RON-tin)


What it isAlpha-2-delta calcium-channel subunit ligand for seizures and postherpetic neuralgia; also used off label for other neuralgia.
Why it mattersSaturable absorption produces diminishing exposure gains as the dose rises, unlike pregabalin.
What it changesReduce in renal impairment; accumulation sedates. Opioids add respiratory depression, and misuse is increasingly recognized.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Postherpetic neuralgia | Adults | 300 mg QD (day 1) → 300 mg BID (day 2) → 300 mg TID (day 3) | 600 mg TID (1800 mg/day) | 1800 mg/day |
| Partial onset seizures | ≥12 yr | 300 mg TID | 300–600 mg TID | 3600 mg/day |
| Partial onset seizures | Peds 3–11 yr | 10–15 mg/kg/day TID | 3–4 yr: 40 mg/kg/day; 5–11 yr: 25–35 mg/kg/day |
Renal Adjust by creatinine clearance in patients ≥12 yr; reduce dose for renal impairment and supplement after hemodialysis
Hepatic Undefined
Max interval between doses ≤12 h
Available strengths
Pregnancy Available data do not indicate increased risk of major birth defects/miscarriage; developmental toxicity in animals; neonatal withdrawal reported with concomitant opioids near delivery
Lactation Secreted in human milk; effects on infant unknown
| Strength | #/mo | generic $/mo | CostPlus | |
|---|---|---|---|---|
| 100 mg | cap | 30 qd | $0.66 | not offered |
| 200 mg | cap | 30 qd | not offered | |
| 300 mg | cap | 30 qd | $0.94 | not offered |
| 400 mg | cap | 30 qd | $1.27 | not offered |
Other forms: Gabapentin ER (GRALISE)
Generic entry2003
NO BOXED WARNINGS
Principal riskSedation and dizziness, additive with opioids
Legacy pregnancy categoryC
Defining liabilitySedation, dizziness and misuse potential; respiratory depression increases with opioids.
Open Gabapentin in the interactive console ↗
